Convergent pathobiologic model of Parkinson's disease

被引:0
|
作者
Maguire-Zeiss, KA
Federoff, HJ
机构
[1] Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA
关键词
Parkinson's disease; synuclein; single-chain antibodies; transgenic animals;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The etiology of Parkinson's disease (PD) has yet to be delineated. Human genetic studies as well as neurotoxicant and transgenic animal models of PD suggest that multiple events trigger the initiation of this progressive age-related neurodegenerative disorder. In addition, we propose that despite disparate disease triggers a convergent pathobiologic pathway exists leading to cell death. The common pathway model posits that both familial and sporadic forms of Parkinson's disease obligately share a common pathophysiological substrate. Herein we discuss the evidence for a common pathway model of Parkinson's disease through a review of synuclein transgenic models and outline an approach for the identification of shared therapeutic targets. We end with a discussion of a potential alternative therapy for Parkinson's disease.
引用
收藏
页码:152 / 166
页数:15
相关论文
共 50 条
  • [21] Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology
    Herve Rhinn
    Liang Qiang
    Toru Yamashita
    David Rhee
    Ari Zolin
    William Vanti
    Asa Abeliovich
    Nature Communications, 3
  • [22] Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease
    Kumaran, Ravindran
    Cookson, Mark R.
    HUMAN MOLECULAR GENETICS, 2015, 24 : R32 - R44
  • [23] Parkinson's - Divergent causes, convergent mechanisms
    Greenamyre, JT
    Hastings, TG
    SCIENCE, 2004, 304 (5674) : 1120 - 1122
  • [24] Animal Model for Prodromal Parkinson's Disease
    Taguchi, Tomoyuki
    Ikuno, Masashi
    Yamakado, Hodaka
    Takahashi, Ryosuke
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (06)
  • [25] An in vivo rat model for Parkinson's disease
    Loopuijt, LD
    EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 : 318 - 318
  • [26] Experimental model of developing of Parkinson's disease
    Tukhtamishev, M.
    Akhmedova, F.
    MOVEMENT DISORDERS, 2019, 34 : S734 - S734
  • [27] Dimebon™ is neuroprotective in a model of Parkinson's disease
    Staal, R. G. W.
    Kubek, K.
    Sung, A.
    Lin, Q.
    DenBleyker, M.
    Monaghan, M.
    Martone, R.
    Robichaud, A. J.
    Haydar, S. N.
    Pangalos, M.
    Reinhart, P. H.
    Hirst, W. D.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S110 - S110
  • [28] The cybrid model of sporadic Parkinson's disease
    Trimmer, Patricia A.
    Bennett, James P., Jr.
    EXPERIMENTAL NEUROLOGY, 2009, 218 (02) : 320 - 325
  • [29] Teleost Model as an Alternative in Parkinson's Disease
    Manasa, K.
    Chitra, V
    Tamilanban, T.
    NEUROLOGY INDIA, 2020, 68 (05) : 979 - 984
  • [30] Convergent validity of the non-motor symptoms scale (NMSS) in Parkinson's disease
    Martinez-Martin, P.
    Rodriguez-Blazquez, C.
    Abe, K.
    Bhattacharyya, K. B.
    Bloem, B. R.
    Carod-Artal, J.
    Dill, B.
    Esselink, R.
    Falup-Pecurariu, C.
    Gallardo, M.
    Mir, P.
    Naidu, Y.
    Nicoletti, A.
    Sethi, K.
    Tsuboi, Y.
    van Hilten, J. J.
    Visser, M.
    Zappia, M.
    Chandhuri, K. R.
    MOVEMENT DISORDERS, 2009, 24 : S385 - S385